Doctors accept information from Big Pharma at face value and ask patients to trust in the statistics they use to determine levels of risk for bone densit. However, they can fail to either appreciate a patient’s own research or their discomfort with the “facts” the doctor is using to inform that patient. Sara Denton shares her own experience.
Off-label prescribing, although legal for physicians in Canada, is illegal for pharmaceutical companies to promote and fines have been ineffective in preventing this practice. Many off-label prescriptions are for conditions difficult to test for, are aimed at women or children and can have serious adverse effects. Drug companies should be required to collect systematic scientific data on these drugs and medical products and seek market authorization for these uses.
The number of individuals living with the sexual side-effects of polypharmacy without informed consent has skyrocketed in recent years. Many seem stunned at suffering from an iatrogenic disorder; that is, a disorder caused by medical, drug or surgical treatment. The side-effects are well established yet not communicated to patients.
Around the globe, medicines regulators approve new drugs after reviewing data from clinical trials. It is these trial data that underlie assuring determinations, like those made by the US Food […]
An examination of compulsive hoarding in light of upgrading it to its own classification in the newest DSM release.
Calls for a Homeland Security approach to mental illness provides for the creation of an “at risk” population that is not only treatable but incurable…and highly profitable.
The family physician, a dying breed, already replaced by better paid second- and third-line technical specialists then proactive laboratory-based preventive measures based on schedules to screen for anomalies in plasma molecules, in body images and soon in genetic material that treat the “molecules” rather than the patient — all to address risks that are almost certainly exaggerated.